我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

生物可吸收支架在冠脉分叉病变中的应用经验

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第6期
页码:
731-734,739
栏目:
综述
出版日期:
2017-06-01

文章信息/Info

Title:
Clinical experience of utilizing bioresorbable vascular scaffolds in the treatment of coronary bifurcation lesions
作者:
赵 瑞1满万荣2顾 菁3孙冬冬2
(1.兰州总医院心电图室,甘肃 兰州730050;
第四军医大学:2.西京医院心血管内科,3.基础医学院外语教研室,陕西 西安 710032)
Author(s):
ZHAO Rui1 MAN Wan-rong2 GU Jing3 SUN Dong-dong2
(1.Department of Electrocardiogram, PLA Lanzhou General Hospital, Lanzhou 730050, Gansu, China;
2.Department of Cardiology, Xijing Hospital, 3.Department of Foreign Languages, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
冠状动脉分叉病变生物可吸收支架经皮冠状动脉介入治疗
Keywords:
coronary bifurcation lesions bioresorbable vascular scaffold percutaneous coronary intervention
分类号:
R618
DOI:
-
文献标识码:
A
摘要:
生物可吸收支架的出现为冠状动脉分叉病变介入治疗提供了一种全新的策略。然而由于分叉病变的复杂性,在植入生物可吸收支架过程中还有多种技术手段可供选择。因此,本文旨在综合国外临床经验的基础上,对冠脉分叉病变应用生物可吸收支架策略选择做一综述。
Abstract:
Bioresorbable vascular scaffolds have been introduced as a novel strategy in treatment of coronary bifurcation lesions. Different strategies are employed to insert bioresorbable vascular scaffolds related to the complexity of bifurcation lesions. On the basis of clinical experience both at home and abroad, this manuscript reviews the choices of various strategies used to insert bioresorbable vascular scaffolds.

参考文献/References

[1]Lassen JF,Holm NR,Banning A,et al.Percutaneous coronary intervention for coronary bifurcation disease:11th consensus document from the European Bifurcation Club[J].EuroIntervention,2016,12(1):38-46.
[2]Diletti R,Garcia-Garcia HM,Bourantas CV,et al.Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial[J].Heart,2013,99(17):1267-1274.
[3]Serruys PW,Garcia-Garcia HM,Onuma Y.From metallic cages to transient bioresorbable scaffolds:change in paradigm of coronary revascularization in the upcoming decade?[J].Eur Heart J,2012,33(1):16-25.
[4]Farb A,Burke AP,Kolodgie FD,et al.Pathological mechanisms of fatal late coronary stent thrombosis in humans[J].Circulation,2003,108(14):1701-1706.
[5]Gogas BD,King SR,Samady H.Bioresorbable polymeric scaffolds for coronary revascularization:Lessons learnt from ABSORB III,ABSORB China,and ABSORB Japan[J].Glob Cardiol Sci Pract,2015,2015(5):62.
[6]Gao R,Yang Y,Han Y,et al.Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease:ABSORB China Trial[J].J Am Coll Cardiol,2015,66(21):2298-2309.
[7]Muramatsu T,Onuma Y,Garcia-Garcia HM,et al.Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold:an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials[J].JACC Cardiovasc Interv,2013,6(3):247-257.
[8]Dzavik V,Colombo A.The absorb bioresorbable vascular scaffold in coronary bifurcations:insights from bench testing[J].JACC Cardiovasc Interv,2014,7(1):81-88.
[9]纪兆乐,胡建华,杨亚丽,等.全吸收式血管支架的临床研究进展[J].心脏杂志,2016(6):727-730.
[10]Louvard Y,Thomas M,Dzavik V,et al.Classification of coronary artery bifurcation lesions and treatments:time for a consensus![J].Catheter Cardiovasc Interv,2008,71(2):175-183.
[11]Diletti R,Onuma Y,Farooq V,et al.6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm[J].J Am Coll Cardiol,2011,58(3):258-264.
[12]Ormiston JA,Webber B,Ubod B,et al.Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations:a bench study of deployment,side branch dilatation and post-dilatation strategies[J].EuroIntervention, 2015,10(10):1169-1177.
[13]Burzotta F,Trani C,Todaro D,et al.Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach[J].JACC Cardiovasc Interv,2011,4(3):327-335.
[14]Kimura T,Kozuma K,Tanabe K,et al.A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs.everolimus-eluting metallic stents in patients with coronary artery disease:ABSORB Japan[J].Eur Heart J,2015,36(47):3332-3342.
[15]Huo Y,Finet G,Lefevre T,et al.Optimal diameter of diseased bifurcation segment: a practical rule for percutaneous coronary intervention[J].EuroIntervention,2012,7(11):1310-1316.
[16]Gomez-Lara J,Diletti R,Brugaletta S,et al.Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study[J].EuroIntervention,2012,8(2):214-224.
[17]Finet G,Gilard M,Perrenot B,et al.Fractal geometry of arterial coronary bifurcations:a quantitative coronary angiography and intravascular ultrasound analysis[J].EuroIntervention,2008,3(4):490-498.
[18]Hildick-Smith D,Lassen JF,Albiero R,et al.Consensus from the 5th European Bifurcation Club meeting[J].EuroIntervention,2010,6(1):34-38.
[19]van Geuns RJ,Gogas BD,Farooq V,et al.3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold[J].Int J Cardiol,2011,153(2):e43-e45.
[20]Di Mario C,Foin N,Colombo A.Kissing vanishing stents: are we trading ephemeral benefit for permanent damage?[J].EuroIntervention,2013,9(7):777-779.
[21]Seth A,Sengottuvelu G,Ravisekar V.Salvage of side branch by provisional“TAP technique”using Absorb bioresorbable vascular scaffolds for bifurcation lesions:first case reports with technical considerations[J].Catheter Cardiovasc Interv,2014,84(1):55-61.
[22]Bourantas CV,Papafaklis MI,Kotsia A,et al.Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation:an optical coherence tomography study[J].JACC Cardiovasc Interv,2014,7(3):315-324.
[23]Serruys PW,Onuma Y,Ormiston JA,et al.Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis:six-month clinical and imaging outcomes[J].Circulation,2010,122(22):2301-2312.
[24]Park DW,Park SW,Park KH,et al.Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up[J].Am J Cardiol,2006,98(3):352-356.
[25]Ruzsa Z,van der Linden M,Van Mieghem NM,et al.Culotte stenting with bioabsorbable everolimus-eluting stents[J].Int J Cardiol,2013,168(2):e35-e37.
[26]Lassen JF,Holm NR,Stankovic G,et al.Percutaneous coronary intervention for coronary bifurcation disease:consensus from the first 10 years of the European Bifurcation Club meetings[J].EuroIntervention,2014,10(5):545-560.
[27]van Mieghem N,Wilschut JJ,Ligthart J,et al.Modified T-technique with bioresorbable scaffolds ensures complete carina coverage:an optical coherence tomography study[J].JACC Cardiovasc Interv,2014,7(8):e109-e110.
[28]Colombo A.Contemporary treatment of coronary bifurcations with drug-eluting stent:part II[J].J Interv Cardiol,2006,19(1):51-53.
[29]Sharma SK,Choudhury A,Lee J,et al.Simultaneous kissing stents(SKS)technique for treating bifurcation lesions in medium-to-large size coronary arteries[J].Am J Cardiol,2004,94(7):913-917.
[30]Verheye S,Ormiston JA,Stewart J,et al.A next-generation bioresorbable coronary scaffold system:from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results[J].JACC Cardiovasc Interv,2014,7(1):89-99.
[31]Sato K,Latib A,Panoulas VF,et al.A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting[J].JACC Cardiovasc Interv,2014,7(8):e103-e104.
[32]Okamura T,Onuma Y,Garcia-Garcia HM,et al.3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds:a proposal for classification[J].JACC Cardiovasc Interv,2010,3(8):836-844.

备注/Memo

备注/Memo:
收稿日期:2016-12-06.基金项目:国家自然科学基金项目资助(81570318)
通讯作者:孙冬冬,副教授,主要从事冠心病临床及基础研究 Email:wintersun3@gmail.com
作者简介:赵瑞,主治医师 Email:359703891@qq.com 共同第一作者:满万荣,住院医师,硕士 Email:manwanrong@foxmail.com
更新日期/Last Update: 2017-06-06